Cargando…

Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives

Half of the patients with phaeochromocytoma have glucose intolerance which could be life-threatening as well as causing postoperative hypoglycemia. Glucose intolerance is due to impaired insulin secretion and/or increased insulin resistance. Impaired insulin secretion is caused by stimulating adrene...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Ichiro, Islam, Farhadul, Lam, Alfred King-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726412/
https://www.ncbi.nlm.nih.gov/pubmed/33324347
http://dx.doi.org/10.3389/fendo.2020.593780
_version_ 1783620881714511872
author Abe, Ichiro
Islam, Farhadul
Lam, Alfred King-Yin
author_facet Abe, Ichiro
Islam, Farhadul
Lam, Alfred King-Yin
author_sort Abe, Ichiro
collection PubMed
description Half of the patients with phaeochromocytoma have glucose intolerance which could be life-threatening as well as causing postoperative hypoglycemia. Glucose intolerance is due to impaired insulin secretion and/or increased insulin resistance. Impaired insulin secretion is caused by stimulating adrenergic α2 receptors of pancreatic β-cells and increased insulin resistance is caused by stimulating adrenergic α1 and β3 receptors in adipocytes, α1 and β2 receptors of pancreatic α-cells and skeletal muscle. Furthermore, different affinities to respective adrenergic receptors exist between epinephrine and norepinephrine. Clinical studies revealed patients with phaeochromocytoma had impaired insulin secretion as well as increased insulin resistance. Furthermore, excess of epinephrine could affect glucose intolerance mainly by impaired insulin secretion and excess of norepinephrine could affect glucose intolerance mainly by increased insulin resistance. Glucose intolerance on paraganglioma could be caused by increased insulin resistance mainly considering paraganglioma produces more norepinephrine than epinephrine. To conclude, the difference of actions between excess of epinephrine and norepinephrine could lead to improve understanding and management of glucose intolerance on phaeochromocytoma.
format Online
Article
Text
id pubmed-7726412
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77264122020-12-14 Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives Abe, Ichiro Islam, Farhadul Lam, Alfred King-Yin Front Endocrinol (Lausanne) Endocrinology Half of the patients with phaeochromocytoma have glucose intolerance which could be life-threatening as well as causing postoperative hypoglycemia. Glucose intolerance is due to impaired insulin secretion and/or increased insulin resistance. Impaired insulin secretion is caused by stimulating adrenergic α2 receptors of pancreatic β-cells and increased insulin resistance is caused by stimulating adrenergic α1 and β3 receptors in adipocytes, α1 and β2 receptors of pancreatic α-cells and skeletal muscle. Furthermore, different affinities to respective adrenergic receptors exist between epinephrine and norepinephrine. Clinical studies revealed patients with phaeochromocytoma had impaired insulin secretion as well as increased insulin resistance. Furthermore, excess of epinephrine could affect glucose intolerance mainly by impaired insulin secretion and excess of norepinephrine could affect glucose intolerance mainly by increased insulin resistance. Glucose intolerance on paraganglioma could be caused by increased insulin resistance mainly considering paraganglioma produces more norepinephrine than epinephrine. To conclude, the difference of actions between excess of epinephrine and norepinephrine could lead to improve understanding and management of glucose intolerance on phaeochromocytoma. Frontiers Media S.A. 2020-11-26 /pmc/articles/PMC7726412/ /pubmed/33324347 http://dx.doi.org/10.3389/fendo.2020.593780 Text en Copyright © 2020 Abe, Islam and Lam http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Abe, Ichiro
Islam, Farhadul
Lam, Alfred King-Yin
Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title_full Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title_fullStr Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title_full_unstemmed Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title_short Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
title_sort glucose intolerance on phaeochromocytoma and paraganglioma—the current understanding and clinical perspectives
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726412/
https://www.ncbi.nlm.nih.gov/pubmed/33324347
http://dx.doi.org/10.3389/fendo.2020.593780
work_keys_str_mv AT abeichiro glucoseintoleranceonphaeochromocytomaandparagangliomathecurrentunderstandingandclinicalperspectives
AT islamfarhadul glucoseintoleranceonphaeochromocytomaandparagangliomathecurrentunderstandingandclinicalperspectives
AT lamalfredkingyin glucoseintoleranceonphaeochromocytomaandparagangliomathecurrentunderstandingandclinicalperspectives